US equities closed mixed Monday: Dow Jones Industrial Average up 0.29%, S&P 500 down 0.37%, Nasdaq Composite down 1.3%. SpaceX (SPCX.O) plunged 16.4%; Intel (INTC.O) rose 5%; Micron Technology (MU.O) gained about 7%; NVIDIA (NVDA.O) fell 1%. Nasdaq Golden Dragon China Index fell 1.3%; Tencent Music (TME.N) dropped 4%.

Yangjie Technology said sustained upstream increases in wafer chips, bulk metals and packaging materials, and an expected new round of raw-material price hikes in H2 have pushed costs beyond expectations and heightened operating pressure. To safeguard product quality and supply-chain delivery, the company will raise prices across its full product range by 10–15%, with new prices applied to shipments from July 1, 2026.

China's National Medical Products Administration approved Eli Lilly Nederland B.V.'s class-1 innovative drug elacestrant tosylate tablets (brand INLURIYO) for adults with locally advanced or metastatic estrogen receptor–positive (ER+), HER2–negative, ESR1‑mutant breast cancer previously treated with endocrine therapy. Approval covers use as monotherapy and in combination with abemaciclib for the same population, giving Eli Lilly market access in China for an endocrine‑therapy–resistant ER+/HER2– indication.